This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gianella, A. Articles by Sironi, L. Search for Related Content PubMed PubMed Citation Articles by Gianella, A. Articles by Sironi, L.

(American Journal of Pathology. 2007;170:1165-1177.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.060882

Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats

Anita Gianella^*, Elena Nobili^*, Mauro Abbate, Carla Zoja, Paolo Gelosa^*, Luciana Mussoni^*, Stefano Bellosta^*, Monica Canavesi^*, Daniela Rottoli, Uliano Guerrini^*, Maura Brioschi, Cristina Banfi, Elena Tremoli^*, Giuseppe Remuzzi and Luigi Sironi^*

From the Department of Pharmacological Sciences,^* University of Milan, Milan; the Mario Negri Institute for Pharmacological Research, Bergamo; and the Monzino Cardiologic Center, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy

Salt-loaded, spontaneously hypertensive stroke-prone rats show progressive increases in blood pressure and proteinuria and accumulate acute-phase proteins in body fluids, modeling events during renal damage. The aim of this study was to assess the pathological events occurring in the kidney of spontaneously hypertensive stroke-prone rats over time and evaluate the effects of statin treatment, which is known to improve renal and cardiovascular outcomes. Kidneys of male spontaneously hypertensive stroke-prone rats euthanized at different stages of proteinuria showed progressive inflammatory cell infiltration, the accumulation of -smooth muscle actin-positive cells, degenerative changes in podocytes, and severe fibrosis. These were accompanied by an imbalance in the plasminogen/plasmin and metalloprotease systems characterized by the increased renal expression of plasminogen activator inhibitor-1, tissue plasminogen activator, and urokinase plasminogen activator; the net result was an increase in plasmin and matrix metalloproteinase (MMP)-2 and a reduction in MMP-9 activity. Chronic treatment with the hydrophilic rosuvastatin had renoprotective effects in terms of morphology and inflammation and prevented the changes in plasmin, MMP-2, and MMP-9 activity. These effects were independent of the changes in blood pressure and plasma lipid levels. Treatment with the lipophilic simvastatin was not renoprotective. These data suggest that rosuvastatin may have potential utility as a therapeutic option in renal diseases that are characterized by inflammation and fibrosis.

This article has been cited by other articles:

				S. F. Knight, J. Yuan, S. Roy, and J. D. Imig Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension Am J Physiol Renal Physiol, January 1, 2010; 298(1): F86 - F94. [Abstract] [Full Text] [PDF]

				A. Baraka, M. Mikhail, A. Guemei, and S. El Ghotny Effect of Targeting Mitogen-Activated Protein Kinase on Cardiac Remodeling in Rats Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2009; 14(4): 339 - 346. [Abstract] [PDF]

				M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf An Overview of the Extra-Lipid Effects of Rosuvastatin Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174. [Abstract] [PDF]

				M.-S. Zhou, I. H. Schuman, E. A. Jaimes, and L. Raij Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-{beta}, and fibronectin with concomitant increase in nitric oxide bioavailability Am J Physiol Renal Physiol, July 1, 2008; 295(1): F53 - F59. [Abstract] [Full Text] [PDF]

				J. A. Joles Statins and small GTPases: Koch's postulates and chronic kidney disease Nephrol. Dial. Transplant., February 1, 2008; 23(2): 433 - 438. [Full Text] [PDF]